Evidence map›Paper›PMID 41958171›Full record

Observational studyJournal of gynecologic oncology2026

Outcomes of node-positive cervical cancer treated with neoadjuvant chemotherapy followed by radical surgery: a single-center approach to a challenging disease.

Innocenza Palaia, Giorgia Perniola, Noemi Tonti, Federica Tomao, Angelina Pernazza, Giacomo Barchiesi, Lucia Manganaro, Francesca De Felice, Angela Musella, Giulia Paoni Saccone and 7 more

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06752135 (Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06752135 terminatednot on this map

Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a Single Center Experience

TypeobservationalSponsorAzienda Policlinico Umberto IRan2024 to 2024Enrolled97ConditionsCervical CarcinomaArmscervical biopsies/conization,, imaging tests (TCTB, TC-PET, MRI), neoadjuvant chemotherapy (cisplatin or carboplatin plus paclitaxel), hysterectomy, salpingo-oophorectomy, and lymphadenectomy, brachytherapy
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Innocenza PalaiaDepartment of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0003-2346-8696
Giorgia PerniolaDepartment of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0003-0321-9828
Noemi TontiDepartment of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. noemi.tonti@uniroma1.it.ORCID https://orcid.org/0009-0006-3503-5010
Federica TomaoDepartment of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-9738-3102
Angelina PernazzaDepartment of Medical-Surgical Sciences and Biotechnologies, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-8608-2734
Giacomo BarchiesiUOC Oncologia A, Department of Hematology, Oncology and Dermatology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0001-6507-9045
Lucia ManganaroDepartment of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0001-9037-9904
Francesca De FeliceDepartment of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-5119-8358
Angela MusellaDepartment of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-7628-7824
Giulia Paoni SacconeDepartment of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0001-6765-7865
Federica TanziDepartment of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0009-0008-1076-916X
Sofia ManciniDepartment of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0009-0003-1575-1499
Annarita VestriDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-6139-7174
Danilo Alunni FegatelliDepartment of Life Sciences, Health and Health Professions, Link Campus University, Rome, Italy.ORCID https://orcid.org/0000-0001-9726-8617
Pierluigi Benedetti PaniciDepartment of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0001-6752-2039
Ludovico MuziiDepartment of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0001-7195-9583
Violante Di DonatoDepartment of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-9254-5790

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveChemoradiotherapy with brachytherapy (CCRT-B) is the standard treatment for locally advanced cervical cancer (LACC), but prognosis remains poor for patients with lymph node involvement (International Federation of Gynecology and Obstetrics [FIGO] stage IIIC1-2) and bulky disease. This study aimed to evaluate recurrence patterns, salvage therapies, and survival outcomes in patients with FIGO IIIC1-2 cervical cancer (CC) treated with platinum-based neoadjuvant chemotherapy (NACT) followed by radical surgery (RS), and to explore NACT + RS as a potential alternative to CCRT-B.

methodsThis retrospective study included 97 patients with FIGO IIIC1-2 CC treated between 2012 and 2022 at Policlinico Umberto I, Rome. All patients received 3 cycles of platinum-based NACT followed by radical hysterectomy, bilateral salpingo-oophorectomy, and systematic pelvic lymphadenectomy, with para-aortic lymphadenectomy performed if indicated. Adjuvant radiotherapy was given in cases of positive vaginal or parametrial margins; chemotherapy or chemoradiotherapy was administered in patients with lymph node positivity after surgery.

resultsWith a median follow-up of 51 months, 33% of patients died from the disease, 5% from other causes, 58% were alive without disease, and 4% were alive with disease. The 2- and 5-year overall survival (OS) rates were 80.1% and 61.1%, respectively. Progression-free survival was 69.5% at 2 years and 58.5% at 5 years. Median OS after recurrence was 1.01 years. Recurrences occurred primarily in pelvic lymph nodes (22%) and central pelvis (9%).

conclusionsNACT followed by RS offers similar survival outcomes to CCRT-B in node-positive LACC and may be a viable alternative in specialized and well surgical-trained centers.

trial registrationClinicalTrials.gov Identifier: NCT06752135.

Indexed as

Uterine Cervical NeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyChemotherapy, AdjuvantFemaleHumansHysterectomyLymphatic MetastasisLymph Node ExcisionMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesBrachytherapyChemoradiotherapyNeoadjuvant TherapyRadical HysterectomyUterine Cervical Neoplasms

Identifiers

PMID41958171
PMCPMC13655327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.